Early negative minimal residual disease in bone marrow after immunotherapy is less predictive of late or non-marrow relapse among patients with high-risk stage 4 neuroblastoma Academic Article uri icon


MeSH Major

  • Bone Marrow Neoplasms
  • Neoplasm Recurrence, Local
  • Neuroblastoma


  • Molecular detection of minimal residual disease (MRD) measured by quantitative reverse transcription-polymerase chain reaction using a four-marker panel in the bone marrow (BM) after only two treatment cycles of anti-GD2 immunotherapy was a strong independent outcome predictor among high-risk patients with stage 4 neuroblastoma in first remission. While 32 of 46 MRD-negative patients relapsed within 2 years from immunotherapy, only four had marrow relapse; in three of these four patients, MRD turned positive in the subsequent BM. We conclude that negative MRD in the post-cycle two BM was rarely associated with BM relapse, but it did not exclude recurrences at other sites.

publication date

  • July 2013



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1002/pbc.24469

PubMed ID

  • 23335404

Additional Document Info

start page

  • E32

end page

  • 4


  • 60


  • 7